Idorsia Ltd

Swiss Stock Exchange:IDIA.SW

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 496.14 M

Share Price

USD 2.43

Avg Daily Volume

942,766

Change (1 day)

3.67%

Change (1 year)

Change (YTD)

197.61%

Idorsia Ltd Free Cash Flow Yield on June 25, 2025: -82.83%

Idorsia Ltd Free Cash Flow Yield is -82.83% on June 25, 2025. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Idorsia Ltd 52-week low Free Cash Flow Yield is -75.64% on June 25, 2025, which is 8.68% above the current Free Cash Flow Yield.
Idorsia Ltd 52-week low Free Cash Flow Yield is -478.92% on June 25, 2025, which is -478.19% below the current Free Cash Flow Yield.
Idorsia Ltd average Free Cash Flow Yield for the last 52 weeks is -178.63%.

Daily

From:

To:

Zoom:

Key data

Date	Free Cash Flow Yield	Dividend Yield	Market Capitalization	Share Price

Swiss Stock Exchange: IDIA.SW

Idorsia Ltd

CEO	Mr. Andre C. Muller
IPO Date	June 16, 2017
Location	Switzerland
Headquarters	Hegenheimermattweg 91
Employees	636
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.